These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 30278294)

  • 1. Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures.
    Abou-Khalil B; Klein P; Shah A; Ryvlin P; Specchio LM; Gama H; Rocha F; Blum D; Grinnell T; Cheng H; Jung J
    Epilepsy Res; 2018 Nov; 147():80-86. PubMed ID: 30278294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychiatric and cognitive adverse events: A pooled analysis of three phase III trials of adjunctive eslicarbazepine acetate for partial-onset seizures.
    Andermann E; Biton V; Benbadis SR; Shneker B; Shah AK; Carreño M; Trinka E; Ben-Menachem E; Biraben A; Rocha F; Gama H; Cheng H; Blum D;
    Epilepsy Behav; 2018 May; 82():119-127. PubMed ID: 29604484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of the safety and tolerability of eslicarbazepine acetate in older (≥60 years) and younger (18-59 years) adults.
    Andermann E; Rosenfeld W; Penovich P; Rogin J; Cendes F; Carreño M; Ramsay RE; Ben-Menachem E; Gama H; Rocha F; Soares-da-Silva P; Tosiello R; Blum D; Grinnell T
    Epilepsy Res; 2021 Jan; 169():106478. PubMed ID: 33338829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial.
    Sperling MR; Abou-Khalil B; Harvey J; Rogin JB; Biraben A; Galimberti CA; Kowacs PA; Hong SB; Cheng H; Blum D; Nunes T; Soares-da-Silva P;
    Epilepsia; 2015 Feb; 56(2):244-53. PubMed ID: 25528898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy following conversion to eslicarbazepine acetate monotherapy in adults with focal seizures.
    Chung S; Sinha SR; Shah A; Stern JM; Cheng H; Jung J; Grinnell T; Blum D
    Epilepsy Res; 2019 Jul; 153():59-65. PubMed ID: 30999260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis.
    Benbadis S; Klein P; Schiemann J; Diaz A; Elmoufti S; Whitesides J
    Epilepsy Behav; 2018 Mar; 80():129-134. PubMed ID: 29414542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjunctive eslicarbazepine acetate: A pooled analysis of three phase III trials.
    Biton V; Rogin JB; Krauss G; Abou-Khalil B; Rocha JF; Moreira J; Gama H; Trinka E; Elger CE; Cheng H; Grinnell T; Blum D;
    Epilepsy Behav; 2017 Jul; 72():127-134. PubMed ID: 28575761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Tolerability of Adjunctive Eslicarbazepine Acetate in Pediatric Patients (Aged 4-17 Years) With Focal Seizures.
    Mintz M; Pina-Garza JE; Wolf SM; McGoldrick PE; Józwiak S; Grinnell T; Cantu D; Costa R; Moreira J; Li Y; Blum D
    J Child Neurol; 2020 Mar; 35(4):265-273. PubMed ID: 31878820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies.
    Elger C; Koepp M; Trinka E; Villanueva V; Chaves J; Ben-Menachen E; Kowacs PA; Gil-Nagel A; Moreira J; Gama H; Rocha JF; Soares-da-Silva P
    CNS Neurosci Ther; 2017 Dec; 23(12):961-972. PubMed ID: 29030894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials.
    Biton V; Gil-Nagel A; Isojarvi J; Doty P; Hebert D; Fountain NB
    Epilepsy Behav; 2015 Nov; 52(Pt A):119-27. PubMed ID: 26414341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of titration schedule and maintenance dose on the tolerability of adjunctive eslicarbazepine acetate: An integrated analysis of three randomized placebo-controlled trials.
    Krauss G; Biton V; Harvey JH; Elger C; Trinka E; Soares da Silva P; Gama H; Cheng H; Grinnell T; Blum D
    Epilepsy Res; 2018 Jan; 139():1-8. PubMed ID: 29127848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study.
    Elger C; Halász P; Maia J; Almeida L; Soares-da-Silva P;
    Epilepsia; 2009 Mar; 50(3):454-63. PubMed ID: 19243424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials.
    Ryvlin P; Dimova S; Elmoufti S; Floricel F; Laloyaux C; Nondonfaz X; Biton V
    Epilepsia; 2022 Aug; 63(8):2024-2036. PubMed ID: 35582748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to baseline seizure count in patients with focal seizures receiving adjunctive eslicarbazepine acetate in a phase IV clinical trial.
    Aboumatar S; Krishnaiengar SR; Cantu D; Zhang Y; Grinnell T
    Clin Neurol Neurosurg; 2023 Feb; 225():107552. PubMed ID: 36657359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine.
    Zaccara G; Giovannelli F; Maratea D; Fadda V; Verrotti A
    Seizure; 2013 Sep; 22(7):528-36. PubMed ID: 23623245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures.
    Altalib H; Grinnell T; Cantu D; Ikedo F; Vieira M; Zhang Y; Blum D
    Epilepsia Open; 2022 Dec; 7(4):616-632. PubMed ID: 35908275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of eslicarbazepine acetate monotherapy in patients converting from carbamazepine.
    Pazdera L; Sperling MR; Harvey JH; Sam MC; Strom LA; Blum D; Grinnell T; Cheng H
    Epilepsia; 2018 Mar; 59(3):704-714. PubMed ID: 29450890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of adjunctive eslicarbazepine acetate on serum lipids in patients with partial-onset seizures: Impact of concomitant statins and enzyme-inducing antiepileptic drugs.
    Mintzer S; Wechsler RT; Rogin JB; Gidal BE; Schwab M; Ben-Menachem E; Carreño M; da Silva PS; Moreira J; Li Y; Blum D; Grinnell T
    Epilepsy Res; 2018 Mar; 141():83-89. PubMed ID: 29499473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of eslicarbazepine acetate as a first or later adjunctive therapy in patients with focal seizures.
    Hixson J; Gidal B; Pikalov A; Zhang Y; Mehta D; Blum D; Cantu D; Grinnell T;
    Epilepsy Res; 2021 Mar; 171():106561. PubMed ID: 33556737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open-label extension study.
    Trinka E; Rocamora R; Chaves J; Moreira J; Ikedo F; Soares-da-Silva P;
    Epilepsia; 2020 Oct; 61(10):2129-2141. PubMed ID: 32944934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.